H

Henry Schein

Global healthcare product distributor and services

Overview

Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.

Significant Headcount Growth

Work here?Claim your company

About Henry Schein

Simplify's Rating
Why Henry Schein is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Enterprise SoftwareFinancial ServicesHealthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Huntington, New York

Founded

1932

Get referred to Henry Schein

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Q3 2026 sales rose 4.0% to $3.5 billion, while U.S. dental merchandise grew 8.6%.
  • Henry Schein raised 2026 non-GAAP EPS guidance to $5.50-$5.56 after strong share gains.
  • The $1.25 billion revolver through 2031 funds buybacks, acquisitions, and working-capital growth.

What critics are saying

  • The $22 million Q3 2026 restructuring charge shows execution pain persists through 2026.
  • Leadership turnover hit operations in October 2026, with three executives moving to senior advisor roles.
  • Litigation and settlement exposure remains active, including opioid-related lawsuits noted in Q3 filings.

What makes Henry Schein unique

  • Henry Schein leads office-based dental distribution, combining products, software, and financing globally.
  • Its private-label and exclusive brands, including Curodont, outgrow branded products and lift margins.
  • The July 2026 HSLT reorganization integrates supply chain and distribution for faster execution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1B

Above

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Paid Vacation
  • Paid Parental Leave
  • Short Term Disability
  • Health Savings Account/Flexible Spending Account
  • Education Benefits

Stock Price

Growth & Insights and Company News

6 month growth

0%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Nov 3rd, 2026
Henry Schein Q3 sales rise 4% to $3.5B as US dental growth lifts 2026 EPS outlook to $5.50-$5.56

Henry Schein reported third-quarter global sales of $3.5 billion, up 4.0% from a year earlier. Adjusted earnings per share rose 19.1% to $1.37, excluding tariff refunds and a prior-year gain. US dental merchandise sales grew 8.6%, driven mainly by volume and market-share gains. GAAP net income was $119 million, compared with $101 million a year earlier. The company raised its 2026 non-GAAP earnings guidance to $5.50–$5.56 per share, from $5.29–$5.39. It kept its sales growth forecast at 4.5% to 5.5%. Henry Schein bought back $125 million of shares in the quarter and expects more than $200 million in operating-income gains from restructuring. Emmanuel Caprais becomes chief financial officer on November 4.

Yahoo Finance
Nov 3rd, 2026
Henry Schein raises 2026 EPS guidance to $5.50–$5.56 as US dental sales rise 8.6%

Henry Schein raised its full-year 2026 non-GAAP earnings per share guidance to $5.50–$5.56, helped by a third-quarter tariff refund worth $0.19 per diluted share and better underlying performance. US dental merchandise sales grew 8.6%, driven mainly by volume rather than price. Management said this points to market share gains among private practices and emerging dental service organisations. The company is pursuing a "Value Creation" plan targeting $200 million in operating income improvements, with a $125 million run rate expected by the end of 2026. It recorded $22 million in restructuring costs in the quarter as it simplifies its structure. Management expects double-digit earnings growth in 2027. Emmanuel Capre will succeed Ronald South as chief financial officer on November 4, 2026.

Yahoo Finance
Sep 30th, 2026
Henry Schein Cares celebrates 25 years with $285M in donations and product contributions

Henry Schein Cares, the corporate citizenship programme of Henry Schein, Inc., is celebrating its 25th anniversary. Since its launch in 2001, the programme has contributed more than $285 million in cash and donated products whilst collaborating with over 5,000 charitable partners worldwide. The programme operates through five pillars: catalysing healthcare access, advancing policies and solutions, relationship building, empowering Team Schein, and sustaining the planet. Key initiatives include supporting the American Dental Association Foundation's Give Kids A Smile programme, which has helped more than 10.2 million underserved children receive oral health services since 2003. Henry Schein celebrated the milestone during UN General Assembly Week in New York City. The company is advancing towards its Net Zero 2050 goal and aims to source 100% renewable energy by 2030.

TipRanks
Sep 22nd, 2026
Henry Schein expands credit facility to $1.25B, extends term to 2031

Henry Schein has amended and restated its revolving credit agreement, expanding aggregate commitments from $1 billion to $1.25 billion. The facility's termination date has been extended to 19 September 2031. The revised facility, arranged with a syndicate of major international banks, adjusts certain financial definitions and covenants. This provides the healthcare distribution company with greater flexibility in its capital structure. Henry Schein intends to use the enlarged credit facility for working capital and general corporate purposes. These include capital expenditures, share repurchases, refinancing existing debt, and funding potential acquisitions. The agreement includes customary representations, warranties, covenants, and events of default. The company supplies dental, medical, and animal health products to office-based practitioners and healthcare organisations in North America and international markets.

Yahoo Finance
Aug 31st, 2026
Henry Schein shares up 13% in Q2 as cost cuts and revenue growth support bullish outlook

MD Sass Concentrated Value Strategy highlighted Henry Schein as a notable contributor in its second-quarter 2026 investor letter. The healthcare solutions provider saw its shares appreciate 13% during the quarter. The asset management firm believes significant cost reductions combined with accelerating revenue growth should lead to material positive earnings revisions moving into the fourth quarter and 2027. MD Sass met with Henry Schein's new chief executive officer, Fred Lowery, and expects his distribution experience and operational approach to improve efficiencies, margins, and market share. The firm's estimates remain well above consensus over the next several years. Henry Schein closed at $89.52 per share on 28 August 2026, with a market capitalisation of $9.98 billion.

Recently Posted Jobs

Sign up to get curated job recommendations

Henry Schein is Hiring for 221 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs